1. Introduction {#sec1}
===============

Lung cancer is the leading cause of cancer-related mortality around the world with*only 15*%*of 5-years survival rate*\[[@B1]--[@B3]\]. Approximately 80% of lung cancers are nonsmall cell lung cancer (NSCLC). Nevertheless, over 50% of patients with NSCLC have advanced local invasion and metastasis, when they were admitted to*[the]{.ul}* hospital for diagnosis. They must*receive* the systemic chemotherapy, radiotherapy, or chemoradiotherapy*because they missed the opportunity for operation* \[[@B4]--[@B6]\]. As first- or second-line chemotherapy,*taxane agents including paclitaxel (taxol) and docetaxel (taxotere)* are widely used in NSCLC. But they have different acute/subacute toxicity, which results in poor prognosis with only 15% of 5-years survival rate and substandard quality of life (QOL) \[[@B7], [@B8]\]. Therefore, new effective strategies with attenuation and synergistic efficacy are urgently needed.

As Cantharis and Astragalus-based Chinese herbs, Aidi injection (Z52020236, China Food and Drug Administration) is composed of the extracts of Cantharis, Astragalus, Eleutherococcus senticosus, and Ginseng, which appear to have antitumor efficacy and reduce the toxicity \[[@B9]--[@B13]\]. Meta-analysis (Wang, Q. 2010) \[[@B14]\] reported that Aidi injection plus paclitaxel or docetaxel and cisplatin could significantly improve the clinical efficiency and QOL in NSCLC. The combination had low risk of neutropenia, thrombocytopenia, and nausea/vomiting,*but unclear risk*of anemia, hepatotoxicity, nephrotoxicity, neurotoxicity, and alopecia. However, many studies \[[@B15]--[@B18]\] showed that docetaxel and paclitaxel had different clinical manifestations, especially the acute/subacute toxicity. Docetaxel is one of the important first- or second-line chemotherapeutic agents for NSCLC \[[@B19]--[@B21]\]. And docetaxel-based chemotherapy refers to docetaxel alone or plus cisplatin, carboplatin, oxaliplatin, lobaplatin,*or*nedaplatin, which are important chemotherapy regimens in NSCLC. The application of Aidi injection plus docetaxel-based chemotherapy was clinically*used* in a wide range of*treatment.*Can Aidi injection plus docetaxel-based chemotherapy improve clinical efficacy with*satisfying level of safety*in NSCLC? Has Aidi injection attenuated and synergistic efficacy to docetaxel-based chemotherapy in NSCLC? Many studies \[[@B22]--[@B25]\] had shown that Aidi injection plus docetaxel*-*based chemotherapy might improve the clinical efficacy and QOL with low*risk of*acute/subacute toxicity in NSCLC. However, these conclusions*vary* in different studies with limited sample size. At present, there is a*lack*of strong evidence to*prove the efficacy of the treatments*. Therefore, to further reveal its real clinical*efficacy* and provide the best evidence for clinical strategies in NSCLC, we systematically evaluated all the related studies.

2. Materials and Methods {#sec2}
========================

This article followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA guidelines). Ethical approval was not required, as materials of this study*were*published or unpublished studies.

2.1. Search Strategy {#sec2.1}
--------------------

Two reviewers (Chengqiong Wang and Lianhong Li) independently searched articles in Chinese and English databases using the search strategy (Aidi OR Aidi injection OR Compound cantharis injection OR Compound disodium cantharidinate injection or Addie injection) and the search strategy (Taxoids OR Docetaxel OR Docetaxel OR Taxotere) and the search strategy ("Lung Neoplasms"\[Mesh\] OR Lung cancer OR Lung cancers OR Non small cell lung cancer OR NSCLC OR SCLC OR Pulmonary neoplasms OR Lung neoplasm OR Pulmonary neoplasm OR Pulmonary*cancer* OR Pulmonary cancers OR Lung carcinoma OR Pulmonary carcinoma). Published studies were retrieved in Medline, Embase, Web of Science (ISI), China National Knowledge Infrastructure Database (CNKI), Chinese Scientific Journals Full-Text Database (VIP), Wanfang Database, China Biological Medicine Database (CBM) (established to September 2017), and Cochrane Central Register of Controlled Trials (CENTRAL, Issue 8 of 12, August 2017). Ongoing studies were retrieved in Chinese clinical trial registry (Chi-CTR) and US-clinical trials (established to September 2017). All retrievals were implemented by*using*the Mesh and free word. Finally, all related systematic reviews (SRs) or meta-analysis was evaluated, and studies meeting inclusion criteria were selected from the references.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Included studies must meet the following criteria. (1) The patients*had*NSCLC with stages III to IV being diagnosed and confirmed with the histopathological and cytological diagnostic criteria and TNM staging system. (2) There was no severe damage in liver or kidney function in any of the patients. (3) There were randomized controlled trials (RCTs). (4) The experimental group*undergone* Aidi injection plus docetaxel-based chemotherapy, and*the* control group*undergone* docetaxel-based chemotherapy. Docetaxel-based chemotherapy refers to docetaxel alone or plus platinum such as cisplatin, carboplatin, oxaliplatin, lobaplatin, and nedaplatin (DP, DC, DO, DL, and DN). (5) Patients*prior to being included*in the study*have not accepted the* radiotherapy, other chemotherapy, or Chinese herbs. (6) Main outcomes included the clinical efficacy and acute/subacute toxicity. Clinical efficacy was evaluated using tumor responses and QOL. (7) No restrictions were set on the follow-up time or types of hospitals.

Excluded studies must meet the following criteria: (1) duplicates, (2) unrelated studies including studies*concerning*Aidi injection plus paclitaxel chemotherapy, radiotherapy,*additional*chemotherapeutic agents, other Chinese herbs and other themes, (3) non-RCTs including case control studies and series case reports, (4) abstracts*and*reviews without specific data and unrelated SRs, and (5) studies without the clinical efficacy, QOL,*and* acute/subacute toxicity.

2.3. Bias Risk Assessment {#sec2.3}
-------------------------

According to the Cochrane evaluation handbook of RCTs (5.1.0) \[[@B26]\], we evaluated the bias risk of all trials using the bias parameters such as the random sequence generation (selection bias), the allocation concealment (selection bias), the blinding of participants and personnel (performance bias), the blinding of outcome assessment (detection bias), the incomplete outcome data (attrition bias), the selective reporting (reporting bias), and the other bias (whether the baseline is comparable). We judged each parameter on three levels ("yes" for a low risk of bias, "no" for a high risk of bias, and "unclear"). Then, we assessed the trials and categorized them into three levels: low risk (all items were "yes"), high risk (at least one item was "no"), and unclear risk (at least one item was "unclear").

2.4. Selection and Evaluation of Studies {#sec2.4}
----------------------------------------

Two reviewers (Xuemei Tang and Nana Li) independently screened and assessed studies according to the above standards. Any disagreements were eliminated by discussing between themselves or with Zheng Xiao.

2.5. Main Outcomes {#sec2.5}
------------------

We measured the tumor response using objective response rate (ORR) and disease control rate (DCR). According to the World Health Organization (WHO) guidelines for solid tumor responses \[[@B27]\] or Response Evaluation Criteria in Solid Tumors (RECIST) \[[@B28]\], indicators were complete response (CR), partial response (PR), no change (NC), progressive disease (PD), ORR being equal to CR plus PR, and DCR being equal to CR plus PR and NC. According to Karnofsky Performance Status scale (KPS scale) \[[@B29], [@B30]\], QOL was considered to be improved if KPS score increased 10 points or higher after treatment. We measured the acute/subacute toxicity using hematotoxicity such as neutropenia (granulocytes \< 2 × 10^9^/L), thrombocytopenia (platelets \< 100 × 10^9^/L) and anemia (Hemoglobin \< 110g/L), liver dysfunction (serum aminotransferase or alkaline phosphatase \> 1.25 × N), renal dysfunction (serum urea nitrogen or creatinine \> 1.25 × N), hepatorenal dysfunctions, and gastrointestinal toxicity including the gastrointestinal reactions and nausea/vomiting, neurotoxicity (peripheral neuritis), alopecia, rash, phlebitis, and oral mucositis.

2.6. Data Extraction {#sec2.6}
--------------------

Two reviewers (Chengqiong Wang and Lianhong Li) independently extracted all the data in a predesigned data extraction form according to the PICO principle. All the data included the first author, the publishing time, the randomization methods, the demographic characteristics, the sample size, the usage of Aidi injection and the types of docetaxel chemotherapy, the evaluation criteria of clinical efficacy and acute or subacute toxicity and the follow-up*information*, and main outcomes including the ORR, DCR, QOL, and acute or subacute toxicity. The data were obtained directly from the articles. If insufficient details were reported, authors were contacted for further information.

2.7. Statistical Analysis {#sec2.7}
-------------------------

Meta-analysis was implemented by two reviewers (Chengqiong Wang and Jing Li) using Review Manager 5.3 (The Cochrane Collaboration, Oxford, UK). The relative risk (RR) and 95% confidence intervals (CI) were calculated. Statistical heterogeneity of the results across trials was assessed by chi-square based Q-statistic test and the consistency was calculated by I^2^. If the homogeneity (P ≥ 0.1, I^2^ ≤ 50%) was not rejected, the fixed-effects model (FEM) was used to calculate the summary RR and the 95% CI. Otherwise, the results were*calculated* by random-effects model (REM). We performed the subgroup analysis according to different doses of Aidi injection, docetaxel-based chemotherapy and evaluation criteria, which revealed their influence on the tumor responses. Publication bias was evaluated*using* funnel plots*if there were more than 10 included studies.*The poor*quality*studies and studies with over- or underestimated results were important factors*that damage*the robustness of meta-analysis results.*The studies were defined as poor quality studies when they had at least one domain considered as high risk of bias.*The over- or underestimated studies were identified according to the result of funnel plots and heterogeneity analysis, in which*results were statistically different and had positive effects on* publication bias or heterogeneity. Therefore, the sensitivity was evaluated through excluding the*poor quality studies* and studies with overestimated efficacy and underestimated toxicity.

3. Results {#sec3}
==========

3.1. Search Results {#sec3.1}
-------------------

The initial database search identified 286 published studies without ongoing studies using our search strategies ([Figure 1](#fig1){ref-type="fig"}). Reading the title and excluding the duplicates, 114 records were included. After reading the abstract,*51 full texts*and 2 SRs \[[@B14], [@B31]\] were included. And then reading the full text and 17 unqualified studies*excluded*, 36 RCTs \[[@B22]--[@B24], [@B32]--[@B64]\] were included.*After* further evaluating the 2 SRs \[[@B14], [@B31]\], 6 RCTs \[[@B22], [@B32]--[@B34], [@B36], [@B37]\] were included. Finally, we included 36 RCTs \[[@B22]--[@B24], [@B32]--[@B64]\] after excluding 6 RCTs from SRs.

3.2. Characteristics of Included Studies {#sec3.2}
----------------------------------------

In this meta-analysis, we included 36 RCTs \[[@B22]--[@B24], [@B32]--[@B64]\] with 2837 advanced NSCLC patients ([Table 1](#tab1){ref-type="table"}). Docetaxel-based chemotherapy included docetaxel alone, DP, DC, DO, DL, and DN. Experimental group was Aidi injection plus docetaxel-based chemotherapy involving 1422 cases, and control group was docetaxel chemotherapy alone involving 1415 cases. The males and females were 1722 and 1044 cases, respectively, with age between 27 and 82 years. The dosage of Aidi injection was 40 100 ml/day, and treatment time was 1-6 weeks/cycle with 1-6 cycles by intravenous injection. Outcomes were evaluated at 6-12 w after treatment. According to the WHO guidelines \[[@B27]\] for solid tumor responses or RECIST \[[@B65]\], tumor responses were evaluated in 34 studies \[[@B22]--[@B24], [@B32]--[@B55], [@B57]--[@B61], [@B63], [@B64]\] involving 2714 patients. QOL was evaluated in 22 studies \[[@B22]--[@B24], [@B32]--[@B42], [@B44], [@B46]--[@B48], [@B56]--[@B59]\] involving 1676 patients. According to WHO standards \[[@B27]\] or National Cancer Institute Common Toxicity Criteria (NCI-CTC) \[[@B66]\], acute or subacute toxicity was evaluated in 31 studies \[[@B22], [@B23], [@B32]--[@B43], [@B45]--[@B47], [@B49]--[@B55], [@B57], [@B59]--[@B64]\] involving 2434 patients.

3.3. Methodological Bias Risk {#sec3.3}
-----------------------------

In 36 studies,*nine studies*described the random sequence generation using randomized digital table*in eight studies* \[[@B33], [@B43], [@B45], [@B51], [@B55], [@B57], [@B59], [@B61]\] and*lottery in one study*\[[@B24]\]. The random allocation concealment was implemented using envelope in one study \[[@B34]\],*and other*studies did not provide the detailed information about it.*None of the studies*did provide the detailed information about blinding of participants, personnel, and outcome assessment. All studies had complete outcome data without loss to follow-up. Nine studies \[[@B23], [@B36], [@B38], [@B40], [@B47], [@B54], [@B56], [@B57], [@B60]\] had selective reporting about the acute/subacute toxicity. Except for two studies \[[@B37], [@B52]\], baseline*was* comparable in other studies.*The methodological bias risk* of all included studies is presented in [Figure 2](#fig2){ref-type="fig"}.

3.4. Tumor Response {#sec3.4}
-------------------

Thirty-four studies with 2714 cases \[[@B22]--[@B24], [@B32]--[@B55], [@B57]--[@B61], [@B63], [@B64]\] were reported the ORR ([Figure 3](#fig3){ref-type="fig"}). Pearson\'s chi-square test and I^2^ test showed that there was no statistical heterogeneity among studies (I^2^ = 0%). Meta-analysis showed that the ORR had*statistical differences* between Aidi injection plus docetaxel-based chemotherapy and docetaxel-based chemotherapy alone \[RR = 1.30, 95% CI (1.19, 1.42), and P \< 0.00001\] by FEM. Thirty-three studies with 2664 cases reported the DCR ([Figure 4](#fig4){ref-type="fig"}). There was no statistical heterogeneity between studies (I^2^ = 0%). Meta-analysis showed that the DCR had*statistical differences* between the two groups \[RR = 1.17, 95% CI (1.12, 1.22), and P \< 0.00001\] by FEM.

3.5. QOL {#sec3.5}
--------

*The QOL was evaluated according to KPS scale*\[[@B29], [@B30]\]. Twenty-two studies with 1676 cases reported the QOL ([Figure 5](#fig5){ref-type="fig"}). There was minimal heterogeneity among studies (I^2^ = 12%). Meta-analysis showed that the QOL had*statistical differences*between the two groups \[RR = 1.73, 95% CI (1.54, 1.95), and P \< 0.00001\] by FEM.

3.6. Acute/Subacute Toxicity {#sec3.6}
----------------------------

Thirty-one studies \[[@B22], [@B23], [@B32]--[@B43], [@B45]--[@B47], [@B49]--[@B55], [@B57], [@B59]--[@B64]\] involving 2434 patients reported the acute or subacute toxicity. There was heterogeneity among studies in neutropenia (I^2^ = 73%), gastrointestinal toxicity (I^2^ = 88%) and neurotoxicity (I^2^ = 56%), minimal heterogeneity in rash (I^2^ = 2%), and no heterogeneity in others toxicity (I^2^ = 0%). Meta-analysis showed that Aidi injection plus docetaxel-based chemotherapy had lower risk of neutropenia \[RR = 0.70, 95% CI (0.61, 0.79), and P \< 0.00001\] and gastrointestinal toxicity \[RR = 0.76, 95% CI (0.65, 0.89), and P = 0.0006\] than*that of*docetaxel-based chemotherapy alone using REM and lower risk of thrombocytopenia \[RR = 0.63, 95% CI (0.53, 0.75), and P \< 0.00001\], anemia \[RR = 0.60, 95% CI (0.48, 0.75), and P \< 0.00001\], hepatorenal dysfunctions \[RR = 0.56, 95% CI (0.36, 0.88), and P = 0.01\], and alopecia \[RR = 0.58, 95% CI (0.36, 0.93), and P = 0.02\] than*that of*control group using FEM. And all differences were statistically significant ([Table 2](#tab2){ref-type="table"} and Figures [S1](#supplementary-material-1){ref-type="supplementary-material"}, [S2](#supplementary-material-1){ref-type="supplementary-material"}, [S3](#supplementary-material-1){ref-type="supplementary-material"}, [S4](#supplementary-material-1){ref-type="supplementary-material"}, [S5](#supplementary-material-1){ref-type="supplementary-material"}, and [S7](#supplementary-material-1){ref-type="supplementary-material"}). There were no statistical differences in liver dysfunction \[RR = 0.69, 95% CI (0.47, 1.01), and P = 0.05\], renal dysfunction \[RR = 0.56, 95% CI (0.31, 1.00), and P = 0.05\], neurotoxicity \[RR = 0.65, 95% CI (0.35, 1.18), and P = 0.16\], rash \[RR = 0.75, 95% CI (0.38, 1.49), and P = 0.42\], phlebitis \[RR = 1.00, 95% CI (0.63, 1.59), and P = 1.00\], and oral mucositis \[RR = 0.64, 95% CI (0.38, 1.09), and P = 0.10\] between the two groups ([Table 2](#tab2){ref-type="table"} and Figures [S5](#supplementary-material-1){ref-type="supplementary-material"}, [6](#supplementary-material-1){ref-type="supplementary-material"}, and [7](#supplementary-material-1){ref-type="supplementary-material"}).

3.7. Subgroup Analysis of ORR and DCR {#sec3.7}
-------------------------------------

Subgroup analysis was performed to reveal the influence of different doses, docetaxel chemotherapy protocols, and evaluation criteria on the ORR and DCR. Drug doses included Aidi injection with 100 ml, 80-100 ml, 80 ml, 60 ml, 50 ml, and 40 ml/time. Subgroup analysis showed that, with 100 ml, 80-100 ml, and 50 ml, Aidi injection could increase the ORR and DCR ([Table 3](#tab3){ref-type="table"} and Figures [S8](#supplementary-material-1){ref-type="supplementary-material"}-[9](#supplementary-material-1){ref-type="supplementary-material"}). Docetaxel-based chemotherapy included docetaxel alone, DP, DC, DO, DL, and DN. Subgroup analysis showed that only Aidi injection plus DP, DC, and DO could increase the ORR and DCR ([Table 3](#tab3){ref-type="table"} and Figures [S10](#supplementary-material-1){ref-type="supplementary-material"}-[11](#supplementary-material-1){ref-type="supplementary-material"}). Tumor responses were evaluated using WHO or RECIST criteria. Subgroup analysis showed that Aidi injection plus docetaxel-based chemotherapy could increase the ORR and DCR using the WHO or RECIST criteria ([Table 3](#tab3){ref-type="table"} and*Figures* [S8](#supplementary-material-1){ref-type="supplementary-material"}-[13](#supplementary-material-1){ref-type="supplementary-material"}).

3.8. Publication Bias Analysis {#sec3.8}
------------------------------

The funnel plots were symmetric in ORR and thrombocytopenia (Figures [6(a)](#fig6){ref-type="fig"} and [6(f)](#fig6){ref-type="fig"}). And there was no publication bias in these studies which objectively reported the results. The funnel plots were asymmetric in DCR, QOL, neutropenia, and gastrointestinal toxicity (Figures [6(b)](#fig6){ref-type="fig"}, [6(c)](#fig6){ref-type="fig"}, [6(d)](#fig6){ref-type="fig"}, and [6(e)](#fig6){ref-type="fig"}). These results indicated that there was publication bias in them. The DCR was underestimated in one study \[[@B33]\]. The QOL was overestimated in one study \[[@B49]\] and underestimated in two studies \[[@B52], [@B57]\]. The neutropenia was overestimated in four studies \[[@B33], [@B35], [@B54], [@B59]\] and the gastrointestinal toxicity was overestimated in four studies \[[@B35], [@B39], [@B52], [@B59]\] and underestimated in one study \[[@B41]\].

3.9. Sensitivity Analysis {#sec3.9}
-------------------------

Nine*poor quality*studies \[[@B23], [@B36], [@B38], [@B40], [@B47], [@B54], [@B56], [@B57], [@B60]\] had at least one domain considered as high risk of bias and selective reporting about acute/subacute toxicity ([Table 4(a)](#tab4){ref-type="table"}). They had potential effect on robustness of neutropenia, thrombocytopenia, gastrointestinal toxicity, and oral mucositis. Therefore, the sensitivity was evaluated through excluding poor*quality* studies. After excluding poor*quality* studies, all results had good consistency. There was statistical heterogeneity in neutropenia, gastrointestinal toxicity and neurotoxicity, and minimal heterogeneity in QOL. There was publication bias in DCR, QOL, neutropenia, and thrombocytopenia. Therefore, the sensitivity was evaluated through excluding the studies with overestimated efficacy or underestimated toxicity. Before and after excluding these studies, results had good consistency ([Table 4(b)](#tab4){ref-type="table"}). In all, this meta-analysis had good stability.

4. Discussion {#sec4}
=============

Based on previous meta-analysis \[[@B14], [@B31]\], we*eventually* included 36 RCTs involving 2837 patients with advanced NSCLC.*There were 1722 males and 1044 females, respectively,* with ages between*27 and 82 years.* The usage of Aidi injection was 50 ml-100 ml/day, 2-3 weeks/cycle with 2-3 cycles by intravenous injection. Docetaxel-based chemotherapy included docetaxel alone, DP, DC, DO, DL, and DN. The tumor responses, QOL, and acute or subacute toxicity were evaluated at 6-12 w after treatment.

Docetaxel-based chemotherapy is important first- or second-line chemotherapeutic agents for NSCLC. Can Aidi injection plus docetaxel-based chemotherapy improve the clinical efficacy in NSCLC? Thirty-four studies \[[@B22]--[@B24], [@B32]--[@B55], [@B57]--[@B61], [@B63], [@B64]\] involving 2714 patients were included to evaluate the tumor responses. Meta-analysis showed that Aidi injection plus docetaxel-based chemotherapy could significantly improve the ORR and DCR in NSCLC. But there was significant clinical heterogeneity in them. Further subgroup analysis showed that Aidi injection with 100 ml, 80-100 ml, and 50 ml could increase the ORR and DCR and 50 ml was the main dosage. Combined with DP, DC, and DO, Aidi injection could increase the tumor responses. This meta-analysis involved 34 studies with 2714 cases which ensured sufficient sample size for analysis. The DCR was underestimated and the meta-analysis results had good robustness. All these*were* beneficial to*tumor responses*. But most studies had unclear*bias risk,* which weakened the result\'s reliability. Compared to the previous studies \[[@B14], [@B31]\], this meta-analysis revealed that Aidi injection plus docetaxel-based chemotherapy, especially plus DP, DC, and DO, might significantly improve the ORR and DCR and 50 ml was the main dosage. Our previous meta-analysis \[[@B67], [@B68]\] had shown that Aidi injection plus radiotherapy or gemcitabine and cisplatin (GP) could significantly improve the QOL in patients with lung cancer. Can Aidi injection plus docetaxel-based chemotherapy improve the QOL? To further analyze whether Aidi injection can improve the QOL, 22 studies with 1676 cases were included for analysis. Meta-analysis showed that Aidi injection could significantly improve the QOL. But, QOL was overestimated in one study \[[@B49]\] and underestimated in two studies \[[@B52], [@B57]\]. Sensitivity analysis revealed that QOL had good robustness. But most studies had unclear*bias risk.* Therefore, we believed that Aidi injection might also improve the QOL. Aidi injection is composed of extracts from Astragalus, Eleutherococcus senticosus, Ginseng, and Cantharis. In vitro studies \[[@B69]--[@B72]\] had shown that cantharidin could induce the tumor*cells\'* apoptosis and inhibit the proliferation, migration, and invasion. Animal studies \[[@B73]--[@B75]\] had shown that cantharidin or Ginseng could significantly inhibit the growth of malignant tumor cells. Our previous meta-analysis \[[@B76]\] had revealed that Aidi injection could significantly restore the cellular immunity damaged by platinum-based chemotherapy. In addition, many studies \[[@B77], [@B78]\] had shown that Astragalus, senticosus Eleutherococcus, and Ginseng also had antitumor activity and immune regulation functions. These results provided indirect evidence for the above conclusions. In all, we believe that Aidi injection plus docetaxel-based chemotherapy, especially plus DP, DC, and DO, may significantly increase clinical efficacy and improve QOL in patients with NSCLC. The main dose may be 50 ml/time. Results indirectly indicate that Aidi injection may have synergistic efficacy to docetaxel-based chemotherapy. Unfortunately, So far, there was no reliable evidence to confirm the*long-term synergistic efficacy.*

Docetaxel-based chemotherapy has varying degrees of blood, liver, kidney, and gastrointestinal toxicity due to docetaxel plus platinum \[[@B79]--[@B81]\]. However, can Aidi injection plus docetaxel-based chemotherapy increase the risk of acute/subacute toxicity?*To answer this question,* 31 studies \[[@B22], [@B23], [@B32]--[@B43], [@B45]--[@B47], [@B49]--[@B55], [@B57], [@B59]--[@B64]\] involving 2434 patients were included to reveal the risk of toxicity. Meta-analysis showed that Aidi injection plus docetaxel-based chemotherapy had lower risk of the neutropenia, thrombocytopenia, anemia and gastrointestinal toxicity, hepatorenal dysfunctions, and alopecia*compared to that of*docetaxel-based chemotherapy alone. And there were no significant differences in liver dysfunction, renal dysfunction, neurotoxicity, rash, phlebitis, and oral mucositis between the two groups. The meta-analysis of neutropenia, thrombocytopenia, and gastrointestinal toxicity had sufficient studies and sample size. But there were limited studies and sample size in other meta-analysis, especially*in the meta-analysis of* liver and renal dysfunction, which might lead to insufficient assessment. Sensitivity analysis showed that the merged value of neutropenia, thrombocytopenia, and gastrointestinal toxicity had good robustness. Compared to the previous meta-analysis \[[@B14], [@B31]\], this study further revealed that Aidi injection plus docetaxel-based chemotherapy had*low risk of*the neutropenia, thrombocytopenia, and gastrointestinal toxicity. In addition,*we found that* it also had*low risk of*anemia, hepatorenal dysfunctions, and alopecia. Our previous study \[[@B67]\] had shown that Aidi injection plus GP had low risk of hematological and gastrointestinal toxicity and neurotoxicity in NSCLC. Furthermore, Aidi injection could alleviate the radiotherapy related toxicity, such as myelosuppression, radiation pneumonitis, and esophagitis \[[@B68]\]. These results provided indirect clinical evidence for the above conclusions. Zhu X and et al. \[[@B82], [@B83]\] had reported that Astragalus membranaceus injection (AMI) could promote myelopoiesis through improving the hematopoietic microenvironment and relieving the bone marrow cells apoptosis in mice. Hu, W et al. \[[@B84]--[@B87]\] had revealed that ginsenoside Rg1 also had antimyelotoxicity activity and promotion of myelopoiesis through enhancing the antioxidant and anti-inflammatory capacities of bone marrow mesenchymal stem cells (BMSCs) in vivo. Liu L and et.al \[[@B88]\] had shown that Astragalus injection ameliorated the cisplatin-induced nephrotoxicity through regulating the Bax and Bcl-2 expression in mice. Other study \[[@B89]\]*had shown* that ginsenoside Rg1 also had antioxidant activities which ameliorated the cisplatin-induced hepatic injury through Nrf2 signaling pathway in mice. All these revealed that Astragalus and Ginseng*could ameliorate chemotherapy related toxicity through enhancing* the antimyelotoxicity activity, antiapoptotic, and antioxidant activities. These results provided the basic and mechanism evidence for the above conclusions. In summary, Aidi injection plus docetaxel-based chemotherapy may have low risk of hematotoxicity, gastrointestinal toxicity, and hepatorenal dysfunctions. Based on the optimization of efficacy and safety, results indicated that the*optimal dose* might be 50 ml/time. These results indirectly reveal that Aidi injection may have attenuation*effect*to docetaxel related toxicity.

There were some limitations in this study. Firstly, Chinese and English databases were retrieved but not Japanese and Korean databases. All included studies were published in China, which*may lead* to ethnical bias. Secondly, only 9 studies reported the random allocation method.*No studies provided* the detailed information about the random allocation concealment and the binding. Nine studies had selective reporting about the acute/subacute toxicity. Third, long-term efficacy had not been evaluated. Fourth, most studies reported*the* acute/subacute toxicity using*WHO standards \[[@B27]\] or NCI-CTC \[[@B66]\]*. And there were limited studies and sample size in liver and renal dysfunction, neurotoxicity, and alopecia. All these limitations might lead to an inadequate assessment of the clinical efficacy and safety.

5. Conclusions {#sec5}
==============

The available evidence indicates that Aidi injection plus docetaxel-based chemotherapy, especially plus DP, DC, and DO, may significantly improve the clinical efficacy and QOL in patients with NSCLC.*It may have low risk of hematotoxicity, gastrointestinal toxicity, and hepatorenal dysfunctions.*Results indirectly indicate that Aidi injection may have attenuation and synergistic efficacy to docetaxel chemotherapy. Based on the optimization of efficacy and safety, the results indicated that the*optimal dose* may be 50 ml/time. Unfortunately, whether Aidi injection can improve long-term efficacy is still unclear. Furthermore, many limitations might lead to an inadequate assessment*of* the clinical efficacy and safety. Therefore, we look forward to larger scale*RCTs* or real-world studies*for a more thorough review in* future publications.*Consequently,*we hope that this study will provide valuable evidence for Aidi injection as an important supplementary therapy for malignant tumors.

This work was funded by*Special Funds for Academic Seedlings Training and Innovation at Zunyi Medical College \[Qian Kehe Pingtai Rencai no. (2017) 5733-034\]*; Special funds for Science and Technology Research of Traditional Chinese and National Medicine in Guizhou*(no. QZYY 2017-084)*; Joint Fund for Science and Technology of Guizhou Province Science and Technology Hall, Science and Technology Bureau and Affiliated Hospital of Zunyi Medical College \[no. (2016)7485\]; High Level Innovative Talent Program in Guizhou*(no. fzc 120171001)*; Development Fund of Evidence Based Transformation in Affiliated Hospital of Zunyi Medical College (no. 2016); Doctoral Fund of Zunyi Medical College (no. F-617); and Planning Fund of Philosophy and Social Science in Guizhou (no. 14GZYB58).
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###### 

Meta-analysis results of acute or chronic toxicity (Figures S1-7). Figure S1: the analysis of neutropenia between the two groups. Meta-analysis showed that Aidi injection plus*docetaxel-based* chemotherapy had low risk of neutropenia \[RR = 0.70, 95% CI (0.61, 0.79), and P \< 0.00001\] using random-effects model. Figure S2: the analysis of thrombocytopenia between the two groups. Meta-analysis showed that Aidi injection plus*docetaxel-based* chemotherapy had low risk of thrombocytopenia \[RR = 0.63, 95% CI (0.53, 0.75), and P \< 0.00001\] using fixed-effects model. Figure S3: the analysis of anemia between the two groups. Meta-analysis showed that Aidi injection plus*docetaxel-based* chemotherapy had low risk of anemia \[RR = 0.60, 95% CI (0.48, 0.75), and P \< 0.00001\] using fixed-effects model. Figure S4: the analysis of gastrointestinal toxicity between the two groups. Meta-analysis showed that Aidi injection plus*docetaxel-based* chemotherapy had low risk of gastrointestinal toxicity \[RR = 0.76, 95% CI (0.65, 0.89), and P = 0.0006\] using random-effects model. Figure S5: the analysis of hepatorenal dysfunctions between the two groups. Meta-analysis showed that Aidi injection plus*docetaxel-based* chemotherapy had low risk of hepatorenal dysfunctions \[RR = 0.56, 95% CI (0.36, 0.88), and P = 0.01\] using fixed-effects model. But there were no statistically significant differences in liver dysfunction \[RR = 0.69, 95% CI (0.47, 1.01), and P = 0.05\], renal dysfunction \[RR = 0.56, 95% CI (0.31, 1.00), and P = 0.05\] between two groups. Figure S6: the analysis of neurotoxicity between the two groups. There were no statistically significant differences in neurotoxicity \[RR = 0.65, 95% CI (0.35, 1.18), and P = 0.16\] between two groups. Figure S7: the analysis of other toxicity between the two groups. Meta-analysis showed that Aidi injection plus*docetaxel-based* chemotherapy had low risk of alopecia \[RR = 0.58, 95% CI (0.36, 0.93), and P = 0.02\] using fixed-effects model. But there were no statistically significant differences in rash \[RR = 0.75, 95% CI (0.38, 1.49), and P = 0.42\], phlebitis \[RR = 1.00, 95% CI (0.63, 1.59), and P = 1.00\], and oral mucositis \[RR = 0.64, 95% CI (0.38, 1.09), and P = 0.10\] between two groups. Subgroup analysis results of ORR and DCR (Figures S8-13). Figure S8: subgroup analysis of ORR via drug doses. Subgroup analysis showed that with 100 ml, 80-100 ml, and 50 ml, Aidi injection could all increase the ORR. Figure S9: subgroup analysis of DCR via drug doses. Subgroup analysis showed that with 100 ml, 80-100 ml and 50 ml, Aidi injection could all increase the DCR. Figure S10: subgroup analysis of ORR via docetaxel-based chemotherapy. Subgroup analysis showed that only Aidi injection plus DP, DC, and DO could increase the DCR. Figure S11: subgroup analysis of DCR via docetaxel-based chemotherapy. Subgroup analysis showed that only Aidi injection plus DP, DC, and DO could increase the DCR. Figure S12: subgroup analysis of ORR via evaluation criteria. Subgroup analysis showed that Aidi injection plus*docetaxel-based* chemotherapy could increase the ORR using the WHO or RECIST criteria. Figure S13: subgroup analysis of DCR via evaluation criteria. Subgroup analysis showed that Aidi injection plus*docetaxel-based* chemotherapy could increase the DCR using the WHO or RECIST criteria.

###### 

Click here for additional data file.

![Articles retrieved and assessed for eligibility.](ECAM2018-7918258.001){#fig1}
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![The analysis of ORR between two groups.](ECAM2018-7918258.003){#fig3}

![The analysis of DCR between two groups.](ECAM2018-7918258.004){#fig4}

![The analysis of QOL between two groups.](ECAM2018-7918258.005){#fig5}

![Publication bias analysis.](ECAM2018-7918258.006){#fig6}

###### 

Characteristics of included studies.

  **First author. year**      **NSCLC(III-IV)**   **Randomized Method**   **Interventions**   **C**                      **Scale(A)**   **Scale(B)**      **Follow-up**   **Outcomes**                           
  --------------------------- ------------------- ----------------------- ------------------- -------------------------- -------------- ----------------- --------------- -------------- ------------- --------- ------------
  Bian, M. 2006 \[[@B32]\]    34/30               44/20                   30-75               Unclear                    Aidi + DP      50 ml/15d/2       DP              WHO            WHO           8 w       O1, O2, O3
  Zhu, Q. 2006 \[[@B33]\]     30/30               32/28                   33-74               Randomized digital table   Aidi + DP      50 ml/10d/3       DP              RECIST         WHO           9 w       O1, O2, O3
  Chen, X. 2007 \[[@B22]\]    32/32               39/25                   47-72               Unclear                    Aidi + DP      50 ml/15-20d/2    DP              WHO            WHO           6 w       O1, O2, O3
  Hou, E. 2008 \[[@B34]\]     35/35               41/29                   34-70               Unclear                    Aidi + DP      50 ml/10d/2       DP              WHO            WHO           6 w       O1, O2, O3
  Jiang, L. 2008 \[[@B35]\]   50/50               69/31                   39-76               Unclear                    Aidi + DP      50 ml/21d/-       DP              WHO            WHO           4 w       O1, O2, O3
  Lin, Q. 2008 \[[@B36]\]     30/30               41/19                   35-73               Unclear                    Aidi + DP      50 ml/14d/2       DP              WHO            WHO           6 w       O1, O2, O3
  Wang, H. 2008 \[[@B37]\]    40/40               51/29                   30-70               Unclear                    Aidi + DP      80-100 ml/14d/2   DP              WHO            WHO           6 w       O1, O2, O3
  Cui, H. 2010 \[[@B38]\]     30/30               39/21                   38-76               Unclear                    Aidi + DP      80-100 ml/8w/1    DP              WHO            WHO           8 w       O1, O2, O3
  Du, Z. 2011 \[[@B23]\]      60/60               94/26                   42-71               Unclear                    Aidi + DP      40 ml/20d/2       DP              WHO            WHO           8 w       O1, O2, O3
  Lin, S. 2011 \[[@B39]\]     42/40               52/30                   32-79               Unclear                    Aidi + DP      50 ml/14d/2       DP              WHO            WHO           4 w       O1, O2, O3
  Tang, L. 2011 \[[@B40]\]    25/25               28/22                   37-74               Unclear                    Aidi + DP      50 ml/14d/2       DP              RECIST         WHO           4 w       O1, O2, O3
  Wang, T. 2011 \[[@B41]\]    49/49               65/33                   30-78               Unclear                    Aidi + DP      80-100 ml/14d/2   DP              WHO            WHO           6 w       O1, O2, O3
  Xing, H. 2011 \[[@B42]\]    35/35               42/28                   60-82               Unclear                    Aidi + TXT     50 ml/15d/2       TXT             WHO            WHO           10 w      O1, O2, O3
  Jiang, S. 2012 \[[@B43]\]   23/23               38/8                    43-70               Randomized digital table   Aidi + DP      50 ml/14d/2       DP              WHO            WHO           6 w       O1, O3
  Shi, L. 2012 \[[@B44]\]     38/38               55/21                   38-72               Unclear                    Aidi + DP      100 ml/14d/2      DP              WHO            No            6 w       O1, O2
  Tang, X. 2012 \[[@B45]\]    36/40               42/34                   38-73               Randomized digital table   Aidi + DP      50 ml/14d/2       DP              RECIST         WHO           6 w       O1, O3
  Chen, Z. 2013 \[[@B24]\]    52/54               72/34                   57-78               Lottery                    Aidi + DP      50 mL/12W/-       DP              RECIST         No            12 w      O1, O2
  Ge, C. 2013 \[[@B46]\]      41/39               52/28                   53-77               Unclear                    Aidi + DP      50 mL/4W/-        DP              WHO            WHO           4 w       O1, O3
  Wu. Y. 2013 \[[@B47]\]      19/19               21/17                   31-68               Unclear                    Aidi + DP      60 ml/10d/2       DP              WHO            WHO           6 w       O1, O2, O3
  Gao, E. 2014 \[[@B48]\]     36/35               37/34                   Unclear             Unclear                    Aidi + DP      50 ml/14d/3       DP              Unclear        No            9 w       O1, O2
  Li, J. 2014 \[[@B49]\]      25/26               19/17                   42-75               Unclear                    Aidi + DO      100 ml/10d/3      DO              WHO            WHO           12 w      O1, O3
  Song, L. 2014 \[[@B50]\]    32/32               41/23                   27-75               Unclear                    Aidi + DC      50 ml/21d/2       DC              WHO            NCI-CTC 2.0   6 w       O1, O3
  Tang, Y. 2014 \[[@B51]\]    47/44               45/46                   46-71               Randomized digital table   Aidi + DO      50 ml/14d/3       DO              WHO            NCI-CTC 3.0   3 y       O1, O3
  Xing, G. 2014 \[[@B52]\]    72/63               92/43                   Unclear             Unclear                    Aidi + DL      100 ml/14d/1-6    DL              WHO            WHO           3 y       O1, O3
  Xu, H. 2014 \[[@B53]\]      23/23               24/22                   52-74               Unclear                    Aidi + DP      50 ml/42d/2       DP              WHO            WHO           6 w       O1, O3
  Gao, Y. 2015 \[[@B54]\]     40/48               59/29                   32-78               Unclear                    Aidi + DP      80 mL/14d/3       DP              RECIST         WHO           9 w       O1, O3
  Li, Z. 2015 \[[@B56]\]      25/25               37/13                   65-80               Unclear                    Aidi + TXT     50 ml/10d/1       TXT             No             Unclear       Unclear   O2
  Hu, Q. 2015 \[[@B55]\]      35/35               41/29                   34-76               Randomized digital table   Aidi + DC      50 ml/14d/2       DC              WHO            WHO           6 w       O1, O3
  Wang, J. 2015 \[[@B58]\]    50/50               58/42                   35-76               Unclear                    Aidi + DP      80-100 ml/14d/2   DP              WHO            No            6 w       O1, O2
  Mo, Y. 2015 \[[@B57]\]      43/43               49/37                   Unclear             Randomized digital table   Aidi + DP      50 ml/14d/1       DP              WHO            WHO           6 w       O1, O2, O3
  Wang, L. 2015 \[[@B59]\]    60/60               74/46                   62-78               Randomized digital table   Aidi + TXT     50 ml/21d/1       TXT             WHO            WHO           Unclear   O1, O2, O3
  Gao, Y. 2016 \[[@B60]\]     50/50               54/36                   32-78               Unclear                    Aidi + DN      80 mL/14d/3       DN              RECIST         WHO           9 w       O1, O3
  He, Z. 2016 \[[@B61]\]      39/39               27/51                   46-70               Randomized digital table   Aidi + DC      -/14d/-           DC              WHO            WHO           Unclear   O1, O3
  Wang, Y. 2016 \[[@B63]\]    23/23               Unclear                 40-70               Unclear                    Aidi + DP      50 ml/10d/2       DP              RECIST         WHO           6 w       O1, O3
  Wang, X. 2016 \[[@B62]\]    37/36               53/20                   Unclear             Unclear                    Aidi + DP      100 ml/7d/2       DP              no             WHO           6 w       O3
  Zhu, J. 2017 \[[@B64]\]     84/84               95/73                   31-75               Unclear                    Aidi + DC      50 ml/14d/1       DC              WHO            WHO           6 w       O1, O3

**Note:** NSCLC: nonsmall cell lung cancer; E/C: experimental group (Aidi injection plus docetaxel-based chemotherapy) /control group (docetaxel-based chemotherapy); M/F: male/female; Aidi (D/T/C): dose/time/cycles; TXT: docetaxel; DP: docetaxel and cisplatin; DC: docetaxel and carboplatin; DO: docetaxel and oxaliplatin; DL: docetaxel and lobaplatin; DN: docetaxel and nedaplatin; scale. A: evaluation criteria of tumor response; scale. B: evaluation criteria of acute/chronic toxicity; RECIST: response evaluation criteria in solid tumors; NCI-CTC: National Cancer Institute Common Toxicity Criteria; O: outcomes; O1: ORR and DCR; O2: QOL; O3: acute /chronic toxicity.

###### 

Meta-analysis results of acute/chronic toxicity (Figures [S1](#supplementary-material-1){ref-type="supplementary-material"}-[7](#supplementary-material-1){ref-type="supplementary-material"}).

  **Outcomes**                                                                                            **Studies**   **Experimental group (Evens/tatol)**   **Control groups (Evens/tatol)**   **SM**   **RR (95**%**CI)**    **I** ^**2**^   **P**
  ------------------------------------------------------------------------------------------------------- ------------- -------------------------------------- ---------------------------------- -------- --------------------- --------------- --------------
  Neutropenia ([Figure S1](#supplementary-material-1){ref-type="supplementary-material"})                 26            452/1007                               627/999                            REM      0.70 \[0.61, 0.79\]   73%             P \< 0.00001
  Thrombocytopenia ([Figure S2](#supplementary-material-1){ref-type="supplementary-material"})            17            153/715                                235/700                            FEM      0.63 \[0.53, 0.75\]   0%              P \< 0.00001
  Anemia ([Figure S3](#supplementary-material-1){ref-type="supplementary-material"})                      9             85/353                                 135/343                            FEM      0.60 \[0.48, 0.75\]   0%              P \< 0.00001
  Gastrointestinal toxicity ([Figure S4](#supplementary-material-1){ref-type="supplementary-material"})   26            504/1060                               634/1053                           REM      0.76 \[0.65, 0.89\]   88%             P = 0.0006
  Liver dysfunction ([Figure S5](#supplementary-material-1){ref-type="supplementary-material"})           7             37/308                                 52/293                             FEM      0.69 \[0.47, 1.01\]   0%              P = 0.05
  Renal dysfunction ([Figure S5](#supplementary-material-1){ref-type="supplementary-material"})           5             15/181                                 26/173                             FEM      0.56 \[0.31, 1.00\]   0%              P = 0.05
  Hepatorenal dysfunctions ([Figure S5](#supplementary-material-1){ref-type="supplementary-material"})    5             23/147                                 40/146                             FEM      0.56 \[0.36, 0.88\]   0%              P = 0.01
  Neurotoxicity ([Figure S6](#supplementary-material-1){ref-type="supplementary-material"})               5             42/192                                 66/184                             REM      0.65 \[0.35, 1.18\]   56%             P = 0.16
  Alopecia ([Figure S7](#supplementary-material-1){ref-type="supplementary-material"})                    3             16/98                                  27/92                              FEM      0.58 \[0.36, 0.93\]   0%              P = 0.02
  Rash ([Figure S7](#supplementary-material-1){ref-type="supplementary-material"})                        2             12/88                                  15/83                              FEM      0.75 \[0.38, 1.49\]   2%              P = 0.42
  Phlebitis ([Figure S7](#supplementary-material-1){ref-type="supplementary-material"})                   3             25/113                                 25/113                             FEM      1.00 \[0.63, 1.59\]   0%              P = 1.00
  Oral mucositis ([Figure S7](#supplementary-material-1){ref-type="supplementary-material"})              3             18/110                                 28/110                             FEM      0.64 \[0.38, 1.09\]   0%              P = 0.10

**Note:** SM: statistical method; REM: random-effects model; FEM: fixed-effects model; RR: risk ratios.

###### 

Subgroup analysis results of ORR and DCR(Figures [S8](#supplementary-material-1){ref-type="supplementary-material"}-[13](#supplementary-material-1){ref-type="supplementary-material"}).

  **Subgroups**                                                                                                                                                                               **Objective response rate (ORR)**   **Disease control rate (DCR)**                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- -------------------------------- ----- --------------------- ---- -------------- ---- ------ ----- --------------------- ----- --------------
  **Total**                                                                                                                                                                                   34                                  2714                             FEM   1.30 \[1.19, 1.42\]   0%   P \< 0.00001   33   2664   FEM   1.17 \[1.12, 1.22\]   3%    P \< 0.00001
                                                                                                                                                                                                                                                                                                                                                                 
  **Different drugs and doses (Figures** [S8](#supplementary-material-1){ref-type="supplementary-material"}-[9](#supplementary-material-1){ref-type="supplementary-material"} **)**                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                 
  Aidi injection (100 ml)                                                                                                                                                                     3                                   262                              FEM   1.39 \[1.08, 1.80\]   0%   P = 0.01       3    262    FEM   1.27 \[1.07, 1.50\]   27%   P = 0.005
  Aidi injection (80-100 ml)                                                                                                                                                                  4                                   338                              FEM   1.37 \[1.13, 1.67\]   0%   P = 0.002      4    338    FEM   1.19 \[1.06, 1.33\]   0%    P = 0.002
  Aidi injection (80 ml)                                                                                                                                                                      2                                   188                              FEM   1.40 \[1.00, 1.95\]   0%   P = 0.05       2    188    FEM   1.25 \[1.00, 1.55\]   0%    P = 0.05
  Aidi injection (60 ml)                                                                                                                                                                      1                                   38                               No    1.25 \[0.40, 3.95\]   No   P = 0.70       1    38     FEM   1.17 \[0.48, 2.83\]   No    P = 0.73
  Aidi injection (50 ml)                                                                                                                                                                      22                                  1690                             FEM   1.27 \[1.14, 1.42\]   4%   P \< 0.0001    21   1640   FEM   1.16 \[1.10, 1.21\]   0%    P \< 0.00001
  Aidi injection (40 ml)                                                                                                                                                                      1                                   120                              No    1.18 \[0.83, 1.68\]   No   P = 0.36       1    120    No    1.06 \[0.92, 1.23\]   No    P = 0.43
  Aidi injection (Unclear)                                                                                                                                                                    1                                   78                               No    1.17 \[0.62, 2.19\]   No   P = 0.63       1    78     FEM   1.20 \[0.99, 1.46\]   No    P = 0.07
                                                                                                                                                                                                                                                                                                                                                                 
  **Different chemotherapy regimens (Figures** [S10](#supplementary-material-1){ref-type="supplementary-material"}-[11](#supplementary-material-1){ref-type="supplementary-material"} **)**                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                 
  Aidi injection plus DP                                                                                                                                                                      24                                  1767                             FEM   1.27 \[1.15, 1.41\]   0%   P \< 0.00001   23   1717   FEM   1.17 \[1.12, 1.24\]   0%    P \< 0.00001
  Aidi injection plus DC                                                                                                                                                                      4                                   380                              FEM   1.36 \[1.05, 1.76\]   0%   P = 0.02       4    380    FEM   1.16 \[1.07, 1.26\]   0%    P = 0.0004
  Aidi injection plus DO                                                                                                                                                                      2                                   142                              FEM   1.37 \[1.02, 1.85\]   0%   P = 0.04       2    142    FEM   1.07 \[0.93, 1.24\]   0%    P = 0.35
  Aidi injection plus DL                                                                                                                                                                      1                                   135                              No    1.41 \[0.99, 2.01\]   No   P = 0.05       1    135    No    1.47 \[1.10, 1.96\]   No    P = 0.009
  Aidi injection plus DN                                                                                                                                                                      1                                   100                              No    1.63 \[1.00, 2.64\]   No   P = 0.05       1    100    No    1.33 \[0.98, 1.82\]   No    P = 0.07
  Aidi injection plus docetaxel                                                                                                                                                               2                                   190                              FEM   1.19 \[0.82, 1.73\]   0%   P = 0.37       2    190    FEM   1.06 \[0.89, 1.26\]   0%    P = 0.52
                                                                                                                                                                                                                                                                                                                                                                 
  **Different evaluation criteria (Figures** [S12](#supplementary-material-1){ref-type="supplementary-material"}-[13](#supplementary-material-1){ref-type="supplementary-material"} **)**                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                 
  WHO Criteria                                                                                                                                                                                27                                  2188                             FEM   1.30 \[1.18, 1.43\]   0%   P \< 0.00001   27   2188   FEM   1.17 \[1.12, 1.22\]   0%    P \< 0.00001
  RECIST                                                                                                                                                                                      7                                   526                              FEM   1.30 \[1.07, 1.57\]   0%   P = 0.008      6    476    FEM   1.18 \[1.06, 1.32\]   41%   P = 0.003

**Note:** DP: docetaxel and cisplatin; DC: docetaxel and carboplatin; DO: docetaxel and oxaliplatin; DL: docetaxel and lobaplatin; DN: docetaxel and nedaplatin; SM: statistical method; RR: *risk ratio;*FEM: fixed-effects model.

###### 

Sensitivity analysis.

###### 

\(a\) Sensitivity analysis by excluding the poor trials.

  **Indicators**              **Number**   **SM**   **RR(95**%**CI)**     **I** ^**2**^   **Excluded studies**                         **Number**   **SM**   **RR(95**%**CI)**     **I** ^**2**^
  --------------------------- ------------ -------- --------------------- --------------- -------------------------------------------- ------------ -------- --------------------- ---------------
  Neutropenia                 26           REM      0.70 \[0.61, 0.79\]   73%             Poor*∗*\[[@B36], [@B47], [@B54], [@B57]\]    22           REM      0.70 \[0.61, 0.80\]   75%
  Thrombocytopenia            17           FEM      0.63 \[0.53, 0.75\]   0%              Poor*∗*\[[@B57]\]                            16           FEM      0.65 \[0.55, 0.76\]   0%
  Gastrointestinal toxicity   26           REM      0.76 \[0.65, 0.89\]   88%             Poor*∗* \[[@B36], [@B38], [@B54], [@B57]\]   22           REM      0.75 \[0.63, 0.89\]   90%
  Oral mucositis              3            FEM      0.64 \[0.38, 1.09\]   0%              Poor*∗*\[[@B57]\]                            3            FEM      0.64 \[0.38, 1.09\]   0%

###### 

\(b\) Sensitivity analysis excluding the under- or over-estimated trials.

  **Indicators**              **Number**   **SM**   **RR(95**%**CI)**     **I** ^**2**^   **Excluded studies**                                                                                                    **Number**   **SM**   **RR(95**%**CI)**     **I** ^**2**^
  --------------------------- ------------ -------- --------------------- --------------- ----------------------------------------------------------------------------------------------------------------------- ------------ -------- --------------------- ---------------
  DCR                         33           FEM      1.17 \[1.12, 1.22\]   0%              Over*∗*\[[@B36], [@B52], [@B64]\]                                                                                       30           FEM      1.16 \[1.11, 1.21\]   0%
  QOL                         22           FEM      1.73 \[1.54, 1.95\]   12%             Over*∗*\[[@B22], [@B33]--[@B39], [@B41], [@B44], [@B48], [@B49], [@B59]\]                                               9            FEM      1.41 \[1.14, 1.74\]   38%
  Neutropenia                 26           REM      0.70 \[0.61, 0.79\]   73%             Under*∗*\[[@B22], [@B34], [@B36], [@B39], [@B43], [@B49], [@B52], [@B57], [@B62], [@B64]\], Over*∗*\[[@B33], [@B35]\]   14           FEM      0.72 \[0.63, 0.81\]   29%
  Thrombocytopenia            17           FEM      0.63 \[0.53, 0.75\]   0%              Under*∗*\[[@B52], [@B59]\]                                                                                              15           FEM      0.66 \[0.54, 0.79\]   0%
  Gastrointestinal toxicity   26           REM      0.76 \[0.65, 0.89\]   88%             Under*∗*\[[@B23], [@B33], [@B41], [@B42], [@B53], [@B63], [@B64]\], Over*∗*\[[@B35]\]                                   18           FEM      0.86 \[0.79, 0.94\]   5%
  Neurotoxicity               5            REM      0.65 \[0.35, 1.18\]   56%             Under*∗*\[[@B41], [@B42]\]                                                                                              3            FEM      1.04 \[0.65, 1.68\]   0%

**Note:** DCR: disease control rate; QOL: quality of life; FEM: fixed-effects model; REM: random-effects model; RR: relative risk; SM: statistical method; CI: confidence interval; poor trials (Poor*∗*) had at least one domain considered as high risk of bias; over*∗* or under*∗*: over- or underestimated trials of which results had statistical difference and positive effects on publication bias and heterogeneity.
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